How should hydroxyzine be dosed for adults, elderly patients, individuals with hepatic or renal impairment, and when co-administered with CYP3A4 inhibitors?

Hydroxyzine Dosing Recommendations

Start hydroxyzine at 25 mg three to four times daily in adults for pruritus or 50-100 mg four times daily for anxiety, but reduce initial doses by 50% in elderly patients and those with hepatic impairment, and exercise caution with CYP3A4 inhibitors due to QT prolongation risk. 1

Standard Adult Dosing

The FDA-approved dosing varies by indication 1:

• Pruritus (allergic conditions): 25 mg three to four times daily
• Anxiety/tension: 50-100 mg four times daily
• Premedication/sedation: 50-100 mg as single dose

These represent the baseline dosing for otherwise healthy adults without organ impairment or drug interactions.

Elderly Patients (≥65 years)

Start at the low end of the dosing range and titrate cautiously. 1 The FDA label explicitly warns that:

• Sedating drugs cause confusion and oversedation in elderly patients
• Elderly patients should be started on low doses and observed closely
• Greater frequency of decreased hepatic, renal, or cardiac function necessitates dose reduction
• First-generation antihistamines like hydroxyzine cause cognitive decline, particularly worrisome in elderly populations 2

Practical approach: Begin with 12.5-25 mg two to three times daily rather than standard adult doses, then titrate based on response and tolerability.

Hepatic Impairment

Reduce the dose by approximately 50% in patients with hepatic dysfunction. 3 Research in primary biliary cirrhosis patients demonstrates:

• Hydroxyzine elimination half-life extends to 36.6 hours (versus ~20 hours in healthy adults)
• Clearance decreases substantially (8.65 mL/min/kg)
• Volume of distribution increases markedly (22.7 L/kg)
• Prolonged antihistamine effects lasting 120-144 hours

The hepatic impairment significantly prolongs drug exposure, requiring dose reduction to prevent excessive sedation and adverse effects. Start with 25 mg twice daily maximum in moderate hepatic impairment and monitor closely for sedation, cognitive effects, and QT prolongation 1, 3.

Renal Impairment

Dose adjustment is generally not required for mild to moderate renal impairment, but use caution in severe renal dysfunction. 1 The FDA label notes:

• The extent of renal excretion has not been fully determined
• Elderly patients with decreased renal function require careful dose selection
• Start at low doses in patients with significant renal impairment

Since hydroxyzine undergoes primarily hepatic metabolism with minimal renal excretion, mild to moderate renal impairment has limited impact. However, reduce doses in severe renal impairment (CrCl <30 mL/min) by 25-50% due to potential accumulation of metabolites and increased sensitivity.

CYP3A4 Inhibitor Co-administration

Exercise extreme caution when combining hydroxyzine with strong CYP3A4 inhibitors due to QT prolongation risk. 1, 4 The FDA label provides explicit warnings:

• Cases of QT prolongation and Torsades de Pointes reported post-marketing
• Caution required during concomitant use of drugs that prolong QT interval
• Risk amplified in patients with pre-existing heart disease, electrolyte imbalances, or arrhythmogenic drug use

Strong CYP3A4 inhibitors include itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, and ritonavir 4. When co-administering with these agents:

• Reduce hydroxyzine dose by 33-50%
• Monitor ECG for QT prolongation
• Correct electrolyte abnormalities before initiating therapy
• Avoid combination in patients with congenital long QT syndrome or recent myocardial infarction

Critical Safety Considerations

All dosing must account for hydroxyzine's potentiating effects on CNS depressants. 1 When used with narcotics, non-narcotic analgesics, or barbiturates, reduce the dosage of these concomitant CNS depressants accordingly.

Bedtime dosing strategy: For patients requiring chronic therapy, consider giving the entire daily dose at bedtime (e.g., 50 mg at bedtime rather than divided doses) to minimize daytime sedation and psychomotor impairment while maintaining antihistamine efficacy 5.

Acute Generalized Exanthematous Pustulosis (AGEP): Discontinue immediately if skin rash develops; do not resume therapy 1.